Evidence map›Paper›PMID 40212430›Full record

ArticleJournal of cutaneous and aesthetic surgery

Effectiveness of intralesional bleomycin in the management of difficult-to-treat and resistant cutaneous warts in a tertiary care teaching hospital in Puducherry: A quasi-experimental study.

Yogindher Singh, Remya Raj Rajamohanan, Senthilvel Vasudevan, Sheela Kuruvila

Abstract read
In one paragraph

Article in Journal of cutaneous and aesthetic surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yogindher SinghDepartment of Dermatology, Sri Venkateswaraa Medical College Hospital and Research Centre, Puducherry, India.
Remya Raj RajamohananDepartment of Dermatology, Indira Gandhi Medical College and Research Institute, Puducherry, India.
Senthilvel VasudevanDepartment of Community Medicine, Sri Venkateswaraa Medical College Hospital and Research Centre, Puducherry, India.ORCID https://orcid.org/0000-0001-7175-3534
Sheela KuruvilaDepartment of Dermatology, Venereology and Leprosy, Aarupadai Veedu Medical College and Hospital, Puducherry, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The objective of this study was to determine the effectiveness of intralesional injection of bleomycin in the management of difficult-to-treat and resistant cutaneous warts. Material and Methods: A total of 54 patients were enrolled in the study, of whom 52 completed it. We administered 0.1% bleomycin over the warts and conducted follow-up at 4, 8, and 12 weeks. If the warts were not completely clear, we administered the next dose of intralesional bleomycin at each visit until the third visit. If the lesions resolved at the third visit, we conducted a telephonic interview for the next follow-up at the end of 12 weeks to record any recurrence of warts and residual side effects. Results: Out of 54 patients enrolled in the study, two were lost to follow-up. About 49 (94.2%) patients had clearance of warts at the end of the study period. About 45 (86.5%) patients had complete resolution of lesions after the first session. Three patients achieved complete clearance after the second treatment session. One patient achieved complete clearance at the end of the 12 Conclusion: The present study demonstrates that intralesional bleomycin is an efficient and safe treatment option in the management of resistant and difficult-to-treat warts.

Indexed as

EffectiveIntralesional bleomycinResistant wartsSafe

Identifiers

PMID40212430
PMCPMC11980710

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.